Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol Optimization of Rapid Antidepressant Effects of Esketamine in Treatment-Resistant Depression
ChiCTR2500115157Phase 4Not yet recruiting
- Sponsor
- Changzhou Second People's Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of esketamine and propofol in major depressive disorder (MDD) (2 arms), sponsored by Changzhou Second People's Hospital. Primary endpoints: Montgomery–Asberg Depression Rating Scale (MADRS) total score and Dissociation/Separation Status Scale. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
esketaminepropofol
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2500115157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115157.